Andere talen Entera Bio Ltd.

Aandelen

ENTX

IL0011429839

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,98 ^USD	-1,00%		-0,50%	+230,00%

08/04	Entera Bio Ltd. Kondigt de publicatie aan van de gegevens van het Fase 2-onderzoek met orale PTH(1-34) Peptidetabletten (EB613) in het Journal of Bone and Mineral Research	CI
26/03	Entera Bio Ltd. Kondigt belangrijke mijlpaal aan in regelgeving voor oraal PTH(1-34) peptide (EB613) Fase 3 Programma: FDA-uitspraak over kwalificatie van BMD als surrogaat eindpunt voor geneesmiddelen tegen osteoporose wordt binnen 10 maanden verwacht	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research	08/04
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	08/04
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months	26/03
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	26/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates	08/03
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement	04/03
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	30/01
Top Premarket Gainers	18/01
Top Premarket Gainers	17/01
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule	03/01
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025	26/12
Entera Bio Ltd. announced that it has received $6.610594 million in funding	22/12
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	20/12
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform	29/11
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	29/11
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development	14/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Entera Bio Ltd.

Aandelen

ENTX

IL0011429839

Andere talen

Filters